Search the Newsreel

Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary

Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA …

Immunic (IMUX) sees Soleus Capital group disclose 4.9% beneficial stake

Soleus Capital Master Fund, L.P. and its related entities have disclosed a 4.9% beneficial ownership stake in Immunic, Inc. (IMUX), totaling 679,200 shares. This includes shares issuable from pre-funded and common warrants. The ownership is based on 13,644,467 shares outstanding as of July 31, …

IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Matthew GlineInvestor Relations - Stephanie Lee Griffin TAKEAWAYS Cash and Cash Equivalents -- $797.8 million as of June 30, 2026, which management stated provides …

Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages

Lyell Immunopharma (NASDAQ:LYEL) has received an average recommendation of "Moderate Buy" from nine brokerages, with an average 12-month price target of $42, significantly higher than its current trading price. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $1.92 …

Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Dimensional Fund Advisors LP significantly increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares to own a total of 1.05 million shares valued at $3.22 million. Other institutional investors also adjusted their positions in Altimmune, which …

What date does Immunic's (IMUX) report Earnings - Earnings Calendar & Announcement

Immunovant stock hits 52-week high at 41.37 USD

Immunovant Inc.'s stock reached a 52-week high of $41.37, reflecting a 169% total return over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. Separately, Roivant Sciences, a related entity, reported …

Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference on 19 August 2026

Immuron Limited CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The biopharmaceutical company, listed on both ASX and NASDAQ, focuses on orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's …

Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

Immunome (NASDAQ:IMNM) shares hit a new 52-week high of $28.04 after Truist Financial raised its price target to $38 from $37, maintaining a "Buy" rating. Despite a larger-than-expected quarterly loss and significant insider selling, analyst sentiment remains largely positive, with a consensus price target …

Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027

Immunome is advancing varegacestat for desmoid tumors after its Phase 3 RINGSIDE study showed an 84% reduction in disease progression or death risk. The FDA has accepted the New Drug Application with a target action date of April 28, 2027, and the company plans …

Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results

Altimmune Inc (ALT) reported Q2 '26 earnings with an EPS of -$0.12, beating the estimated -$0.14 by 11.44%. The company achieved significant clinical milestones, including initiating a Phase 3 MASH trial and positive Phase 2 results in AUD, while also advancing enrollment for its …

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales …

Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com

Immunome director Isaac Barchas sold over $2.19 million worth of company shares in August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales included shares held indirectly by AMBHMC II LLC and directly by Barchas, following which he directly holds 92,211 shares. The sales …

Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial

Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside

Immunome, Inc.'s average 12-month price target has been increased to $36.31 by 13 analysts, up from $35.77, with individual forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% from its August 11 closing price. The …

Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning

Earnings Call Insights: Altimmune (ALT) Q2 2026 MANAGEMENT VIEW * "2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases," said Chairman, CEO & President Jerome Durso, adding, "Last week we announced …

William Blair Maintains Altimmune(ALT.US) With Hold Rating

William Blair has reiterated its Hold rating on Altimmune (ALT.US). This indicates that the analyst firm recommends investors maintain their current position in the stock, without suggesting buying more or selling. The article does not provide specific reasons or financial data behind this rating.

Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT) reported quarterly earnings, beating analyst expectations with a loss of $0.12 per share against an anticipated loss of $0.14. The company announced progress in its pemvidutide programs, including the start of the Phase III MASH trial and positive results from the Phase …

Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says

Altimmune Releases Q2 2026 Financial Results

Altimmune, Inc. (ALT) announced its Q2 2026 financial results, reporting a narrower basic and diluted loss of $0.12 per share compared to the -$0.14 expected loss. The company posted $0 in revenue for the quarter, a 100% decrease from Q2 2025, and a net …

Immunome stock hits 52-week high at 27.68 USD

Immunome Inc. (IMNM) stock has reached a new 52-week high of $27.68, reflecting significant investor confidence with a 1-year change of 175.42%. Despite InvestingPro analysis suggesting the shares may be overvalued, analysts have revised earnings upwards, with price targets ranging from $30 to $40. …

Immunome Inc. SEC Filing (Aug 12, 2026)

This article reports on an Immunome Inc. SEC Filing (Form 144) submitted on August 12, 2026, which details a proposed sale of 11,048 shares of common stock with an aggregate market value of $301,058.00. The filing, accepted by the SEC EDGAR at 11:40 AM …

Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings

Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise

Altimmune reported a narrower-than-expected Q2 2026 loss of $0.12 per share, beating analyst estimates, as the biotech advanced late-stage trials for liver disease and alcohol use disorder. The company's shares rose 3.87% following the announcement. Altimmune highlighted a strong cash position of $519 million, …

Altimmune Q2 Earnings Call Highlights

Altimmune has initiated patient enrollment for its Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in AUD. The company reported positive topline results from its Phase II RECLAIM trial in AUD and completed enrollment for the Phase …

Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary

Immunome Inc. reported Q2 2026 financial results, showing zero revenue and a net loss of $73.1 million, or $(0.65) per diluted share. This is a decline compared to the prior year's Q2 2025, which had $4 million in revenue and a net loss of …

Altimmune (ALT) Q2 Earnings Beat Expectations but Remain Unprofi

Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs

Altimmune reported a net loss of $22.8 million and held $519 million in cash for Q2 2026. The company highlighted significant progress in its pemvidutide programs, including the initiation of the PERFORMA Phase 3 MASH trial, positive topline results from the RECLAIM Phase 2 …

Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100

The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT

The Manufacturers Life Insurance Company reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 47.1% in the first quarter, selling over 45,000 shares but retaining 51,421 shares valued at $1.28 million. Despite this, other institutional investors have increased their positions. Immunovant reported a wider-than-expected quarterly …

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics announced positive Week 16 topline results from its Phase 3 IZAR-1 trial for sonelokimab in biologic-naïve adults with active psoriatic arthritis, meeting all primary and secondary clinical endpoints. Despite the positive results, the stock fell over 6%. The company also reported strong …

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%

Immunic: Q2 Earnings Snapshot

This article provides an earnings snapshot for Immunic's Q2 performance. Due to the limited content provided, specific details regarding financial figures or company performance are not available.